Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This is a study to evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT‐251 administered for 24 weeks in participants with pulmonary arterial hypertension (PAH). Participants completing this study (RELIEF‐PAH) will be eligible to enroll in an open‐label extension study (RELIEF‐PAH OLE) to evaluate the long‐term efficacy, safety, tolerability and pharmacokinetics of JTT‐251 in participants with PAH.
Epistemonikos ID: 30064baa575a33322f1c20bfa095cec301d20a6b
First added on: May 21, 2024